These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study. Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474 [TBL] [Abstract][Full Text] [Related]
3. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182 [TBL] [Abstract][Full Text] [Related]
4. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130 [TBL] [Abstract][Full Text] [Related]
5. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. Mercadante S; Ferrera P; Adile C; Casuccio A J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. Jandhyala R; Fullarton JR; Bennett MI J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337 [TBL] [Abstract][Full Text] [Related]
7. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain]. Überall MA MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092 [TBL] [Abstract][Full Text] [Related]
8. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188 [TBL] [Abstract][Full Text] [Related]
9. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study. Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863 [TBL] [Abstract][Full Text] [Related]
10. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. Masel EK; Landthaler R; Gneist M; Watzke HH Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261 [TBL] [Abstract][Full Text] [Related]
11. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options. Mercadante S Curr Opin Anaesthesiol; 2015 Oct; 28(5):559-64. PubMed ID: 26263120 [TBL] [Abstract][Full Text] [Related]
12. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management . Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907 [TBL] [Abstract][Full Text] [Related]
13. The use of rapid onset fentanyl in children and young people for breakthrough cancer pain. Coombes L; Burke K; Anderson AK Scand J Pain; 2017 Oct; 17():256-259. PubMed ID: 29229211 [TBL] [Abstract][Full Text] [Related]
14. Opioids for the management of breakthrough pain in cancer patients. Zeppetella G; Davies AN Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465 [TBL] [Abstract][Full Text] [Related]
15. Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review. Mercadante S Crit Rev Oncol Hematol; 2018 Feb; 122():60-63. PubMed ID: 29458790 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control. Chiang YH; Lien CT; Su WH; Yen TY; Chen YJ; Lai YL; Lim KH; Dai KY; Chung HP; Hung CY; Leu YS BMC Palliat Care; 2024 Jun; 23(1):150. PubMed ID: 38877477 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406 [TBL] [Abstract][Full Text] [Related]
18. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Mercadante S Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653 [TBL] [Abstract][Full Text] [Related]
19. Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. Mercadante S; Caraceni A; Masedu F; Scipioni T; Aielli F Oncologist; 2020 Feb; 25(2):156-160. PubMed ID: 31862860 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]